We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Just one drug remains effective for the sexually transmitted disease but soon the bacteria may be able to evade it
Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?
Antiviral treatment Paxlovid is being widely prescribed despite questions about its effectiveness
Short break in immune suppression treatment improves antibody production after vaccination while doing little harm
The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven
Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipeline
Drug from Denali Therapeutics offers hope for sufferers of degenerative brain disorder
German biotech’s promising early-stage results make it a sought-after partner
Biotech company hopes to win first US approval for medicine aimed at people addicted to marijuana
Prevention is better than cure — but is too costly for some countries where drug-resistant bacteria are rampant
German biotech maintains guidance but prepares for fall in sales because of jab oversupply
On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets
Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker
The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy
‘Intricate dance’ under way to ensure simplified assessments of new medicines maintain quality and integrity
Move could boost global development of drugs to ease antimicrobial resistance
New drugs are needed as resistance grows but plans to improve incentives are too modest, executives say
Kate Bingham urges fund managers to step up investment in life sciences
To save lives and economies, we must make progress by drawing on lessons from Covid-19
Swiss drugmaker to license antiviral therapeutic after success in early-stage tests
Drugmakers set to take on GSK as they aim to replicate Covid jab success
Researchers say more than 100m suffer ill effects for at least 12 weeks
Lower effectiveness of vaccines against Omicron makes need for antivirals more urgent, says UK BioIndustry Association chair
International Edition
